These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32918272)

  • 1. Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma.
    Florea A; Harris RB; Klimentidis YC; Kohler LN; Jurutka PW; Jacobs ET
    J Gastrointest Cancer; 2021 Sep; 52(3):940-946. PubMed ID: 32918272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between circulating 1,25(OH)₂D concentration and odds of metachronous colorectal adenoma.
    Hibler EA; Molmenti CL; Lance P; Jurutka PW; Jacobs ET
    Cancer Causes Control; 2014 Jul; 25(7):809-17. PubMed ID: 24737199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.
    Thompson PA; Wertheim BC; Roe DJ; Ashbeck EL; Jacobs ET; Lance P; Martínez ME; Alberts DS
    Cancer Prev Res (Phila); 2009 Dec; 2(12):1023-30. PubMed ID: 19952360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma.
    Jacobs E; Martinez ME; Buckmeier J; Lance P; May M; Jurutka P
    J Carcinog; 2011 Feb; 10():3. PubMed ID: 21383962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
    Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
    Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
    Alberts DS; Martínez ME; Hess LM; Einspahr JG; Green SB; Bhattacharyya AK; Guillen J; Krutzsch M; Batta AK; Salen G; Fales L; Koonce K; Parish D; Clouser M; Roe D; Lance P;
    J Natl Cancer Inst; 2005 Jun; 97(11):846-53. PubMed ID: 15928305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Family history of colorectal cancer in first-degree relatives and metachronous colorectal adenoma.
    Jacobs ET; Gupta S; Baron JA; Cross AJ; Lieberman DA; Murphy G; Martínez ME
    Am J Gastroenterol; 2018 Jun; 113(6):899-905. PubMed ID: 29463834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between Circulating Vitamin D Metabolites and Fecal Bile Acid Concentrations.
    Jacobs ET; Haussler MR; Alberts DS; Kohler LN; Lance P; Martínez ME; Roe DJ; Jurutka PW
    Cancer Prev Res (Phila); 2016 Jul; 9(7):589-97. PubMed ID: 27138789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein and risk of colorectal adenomas or serrated polyps: a prospective study.
    Crockett SD; Mott LA; Barry EL; Figueiredo JC; Burke CA; Baxter GJ; Sandler RS; Baron JA
    Cancer Prev Res (Phila); 2014 Nov; 7(11):1122-7. PubMed ID: 25145487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia.
    Hibler EA; Hu C; Jurutka PW; Martinez ME; Jacobs ET
    Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):368-75. PubMed ID: 22144504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
    Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
    Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 21 as a circulating biomarker at various stages of colorectal carcinogenesis.
    Qian J; Tikk K; Weigl K; Balavarca Y; Brenner H
    Br J Cancer; 2018 Nov; 119(11):1374-1382. PubMed ID: 30425347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenium and colorectal adenoma: results of a pooled analysis.
    Jacobs ET; Jiang R; Alberts DS; Greenberg ER; Gunter EW; Karagas MR; Lanza E; Ratnasinghe L; Reid ME; Schatzkin A; Smith-Warner SA; Wallace K; Martínez ME
    J Natl Cancer Inst; 2004 Nov; 96(22):1669-75. PubMed ID: 15547179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced synchronous adenoma but not simple adenoma predicts the future development of metachronous neoplasia in patients with resected colorectal cancer.
    Moon CM; Cheon JH; Choi EH; Kim ES; Park JJ; Han SY; Kim DH; Kim TI; Kim WH
    J Clin Gastroenterol; 2010 Aug; 44(7):495-501. PubMed ID: 20351568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro.
    Serfaty L
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S53-60. PubMed ID: 23141895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of advanced metachronous colorectal adenoma during long-term follow-up.
    Nusko G; Hahn EG; Mansmann U
    Int J Colorectal Dis; 2008 Nov; 23(11):1065-71. PubMed ID: 18597098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development.
    Pearson T; Caporaso JG; Yellowhair M; Bokulich NA; Padi M; Roe DJ; Wertheim BC; Linhart M; Martinez JA; Bilagody C; Hornstra H; Alberts DS; Lance P; Thompson PA
    Cancer Med; 2019 Feb; 8(2):617-628. PubMed ID: 30652422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification of individuals with low-risk colorectal adenomas using clinical characteristics: a pooled analysis.
    Gupta S; Jacobs ET; Baron JA; Lieberman DA; Murphy G; Ladabaum U; Cross AJ; Jover R; Liu L; Martinez ME
    Gut; 2017 Mar; 66(3):446-453. PubMed ID: 26658145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study.
    Jacobs ET; Ahnen DJ; Ashbeck EL; Baron JA; Greenberg ER; Lance P; Lieberman DA; McKeown-Eyssen G; Schatzkin A; Thompson PA; Martínez ME
    Am J Epidemiol; 2009 Mar; 169(6):657-66. PubMed ID: 19147743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the Sum of Adenoma Diameters (Adenoma Bulk) on Index Examination Predict Risk of Metachronous Advanced Neoplasia?
    Anderson JC; Morris CB; Robertson DJ; Barry ELR; Figueiredo JC; Cruz-Correa M; Bostick RM; Ahnen DJ; Baron JA
    J Clin Gastroenterol; 2018 Aug; 52(7):628-634. PubMed ID: 28767463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.